Dr. David M. Baratz, MD
Pulmonology (Pulmonary Disease Physician)
3811 E Bell Rd Ste 107
Phoenix, AZ 85032
Who else practices at this address →
Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Arizona College of Medicine (1985)
- Years since graduation
- 41
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 550
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1985Medical school: University of Arizona College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
AZ license 19963 -
Internal Medicine Physician
AZ license 19963 -
Sleep Medicine (Internal Medicine) Physician
AZ license 19963
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Honor Health John C. Lincoln Medical Center Phoenix, AZ
- Honorhealth Scottsdale Shea Medical Center Scottsdale, AZ
- Honorhealth Scottsdale Thompson Peak Med Ctr Scottsdale, AZ
Medical groups
- Pulmonary Associates PA (16 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 550
- Services billed
- 1,430
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 435 | 280 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 323 | 143 |
| New patient office or other outpatient visit, 60-74 minutes | 95 | 95 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 85 | 78 |
| X-ray of chest, 2 views | 74 | 66 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 66 | 64 |
| Established patient office or other outpatient visit, 30-39 minutes | 61 | 57 |
| Test to determine lung volumes using sensors | 44 | 41 |
| Test to examine how well the lungs exchange gases | 44 | 41 |
| Test to measure expiratory airflow and volume | 32 | 32 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Phoenix, AZ | 1,009 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Phoenix, AZ | 425 |
| Prednisone Other prescribers in Phoenix, AZ | 212 |
| Montelukast Sodium Other prescribers in Phoenix, AZ | 190 |
| Breztri Aerosphere (budesonide/glycopyr/formoterol) Other prescribers in Phoenix, AZ | 189 |
| Anoro Ellipta (umeclidinium brm/vilanterol tr) Other prescribers in Phoenix, AZ | 162 |
| Opsumit (macitentan) | 160 |
| Stiolto Respimat (tiotropium br/olodaterol hcl) Other prescribers in Phoenix, AZ | 158 |
| Roflumilast Other prescribers in Phoenix, AZ | 145 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Phoenix, AZ | 89 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 33 companies reported 213 payments worth $5,215 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $623 |
|---|---|
| GlaxoSmithKline, LLC. | $478 |
| Actelion Pharmaceuticals US, Inc. | $443 |
| Genzyme Corporation | $433 |
| Verona Pharma, Inc. | $381 |
| Regeneron Healthcare Solutions, Inc. | $347 |
| Axsome Therapeutics, Inc. | $329 |
| Jazz Pharmaceuticals Inc. | $222 |
| Food and Beverage | $4,837 |
|---|---|
| Education | $378 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Jazz Pharmaceuticals Inc. May 8, 2025 | Education XYWAV · NEUROLOGY · in-kind | $99.99 |
| Actelion Pharmaceuticals US, Inc. Aug 19, 2025 | Education OPSUMIT; UPTRAVI · Cardiology · in-kind | $99.95 |
| Jazz Pharmaceuticals Inc. May 8, 2025 | Education XYWAV · NEUROLOGY · in-kind | $90.00 |
| Harmony Biosciences LLC Sep 30, 2025 | Education in-kind | $87.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 1 companies. The companies reported $224,812 in research payments for these studies, mostly to the institutions running them.
- A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Hea…
Merck Sharp & Dohme LLC - A Phase 2, Multicenter, Double-blind, Extension Study to Evaluate the Effects of Sotatercept for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserv…
Merck Sharp & Dohme LLC - An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH MK-7962-038
Merck Sharp & Dohme LLC - A Phase 2, Multicenter, Single-blinded, Randomized Study to Evaluate the Pharmacokinetics and Safety of Sotatercept MK-7962 Administered Using Either a Weight-based or Weight-banded Approach in Participants With Pulmo…
Merck Sharp & Dohme LLC - An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.